Novartis cholesterol setback tests hopes for emerging heart disease drugs
Novartis' cholesterol drug pelacarsen failed in a late-stage study, causing its shares to drop 3%. The drug had been expected to generate $3B-$6B in annual sales. Investors now focus on upcoming data for del-desiran and remibrutinib. Rival drugs from Amgen and Eli Lilly face increased pressure. Novartis shares are up 20% YTD.
How this was made
The 30-second read
Why it matters
The failure removes a key growth driver, increasing reliance on other late‑stage assets and pressuring the stock.
Market read
First‑report of a major trial failure for a large‑cap pharma, driving immediate price decline and reshaping expectations for the Lp(a) therapeutic sector.
What to watch
Potential upside from Novartis' anti‑inflammatory drug remibrutinib and other pipeline assets could cushion the hit.
Background
Novartis announced that its Lp(a)‑lowering drug pelacarsen did not meet primary endpoints in a pivotal trial, undermining expectations for a $3‑$6 billion revenue opportunity.
Ticker impact
Novartis' cholesterol drug pelacarsen failed to reduce heart attack and stroke risk in a large late‑stage trial, causing the stock to fall over 3% on Monday.
Short‑term downside pressure; potential further sell‑off if no mitigating news.
First‑report trial failure for a blockbuster‑potential drug, large‑cap impact, and immediate price drop.
Market effects
Lipoprotein(a) therapeutic space faces heightened scrutiny; rivals Amgen and Eli Lilly may see increased interest.
European pharma stocks could see modest pressure as the setback highlights trial risk.
Global investors tracking cardiovascular drug pipelines will adjust risk models.
Counterpoint
If del‑desiran data later in the quarter shows strong efficacy, the market may quickly rebound on the broader pipeline.
Key entities
- companyNovartis
Swiss pharmaceutical giant, ticker NVS.
- companyAmgen
Rival biotech developing olpasiran for Lp(a).
- companyEli Lilly
Rival biotech developing lepodisiran for Lp(a).
